About: Hydroxychloroquine and COVID-19: critiquing the impact of disease public profile on policy and clinical decision-making

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Hydroxychloroquine and COVID-19: critiquing the impact of disease public profile on policy and clinical decision-making Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Hydroxychloroquine and COVID-19: critiquing the impact of disease public profile on policy and clinical decision-making
Creator	Aquino, Ysj Cabrera, N
Source	Medline; PMC
abstract	The controversy surrounding the use of hydroxychloroquine (HCQ), an antimalarial drug, for COVID-19 has raised numerous ethical and policy problems. Since the suggestion that HCQ has potential for COVID-19, there have been varying responses from clinicians and healthcare institutions, ranging from adoption of protocols using HCQ for routine care to the conduct of randomised controlled trials to an effective system-wide prohibition on its use for COVID-19. In this article, we argue that the concept of ‘disease public profile’ has become a prominent, if not the sole, determinant in decision-making across various healthcare responses to the pandemic. In the case of COVID-19, the disease’s public profile is based on clinical and non-clinical factors that include contagiousness, clinical presentation and media coverage. In particular, we briefly examine the dangers of a heightened public profile in magnifying the inequality of diseases and undermining three key ethical concepts, namely (1) evidence-based practice, (2) sustainable allocation and (3) meaningful consent.
has issue date	2020-07-09(xsd:dateTime)
bibo:doi	10.1136/medethics-2020-106306
bibo:pmid	32647045
has license	no-cc
sha1sum (hex)	3635ed81767d36915746f3a0d450b31914fc97cd
schema:url	https://doi.org/10.1136/medethics-2020-106306
resource representing a document's title	Hydroxychloroquine and COVID-19: critiquing the impact of disease public profile on policy and clinical decision-making
has PubMed Central identifier	PMC7371492
has PubMed identifier	32647045
schema:publication	J Med Ethics
resource representing a document's body	covid:3635ed81767d36915746f3a0d450b31914fc97cd#body_text
is schema:about of	named entity 'decision-making' named entity 'Hydroxychloroquine' named entity 'COVID-19' named entity 'COVID-19' named entity 'Hydroxychloroquine' named entity 'resource allocation' named entity 'influenza' named entity 'pink ribbon' named entity 'COVID' named entity 'HCQ' named entity 'adverse outcome' named entity 'US FDA' named entity 'HCQ' named entity 'clinical practice' named entity 'COVID' named entity 'COVID' named entity 'prognosis' named entity 'arrhythmias' named entity 'COVID-19' named entity 'HCQ' named entity 'COVID' named entity 'off-label' named entity 'clinical practice' named entity 'lupus' named entity 'COVID-19' named entity 'COVID-19' named entity 'trickles' named entity 'clinical research' named entity 'intracellular' named entity 'US Centers for Disease Control and Prevention' named entity 'HCQ' named entity 'case reports' named entity 'Catch-22' named entity 'Off-label' named entity 'COVID' named entity 'adverse events' named entity 'malaria' named entity 'scientific evidence' named entity 'off-label' named entity 'lupus' named entity 'HCQ' named entity 'motor neuron disease' named entity 'clinical outcomes' named entity 'COVID' named entity 'medical conditions' named entity 'non-clinical' named entity 'COVID' named entity 'President Trump' named entity 'comorbidities' named entity 'The Lancet' named entity 'mode of transmission' named entity 'prophylaxis' named entity 'HCQ' named entity 'RCTs' named entity 'aminoquinolines' named entity 'case-fatality rate' named entity 'probability' named entity 'BMJ' named entity 'COVID' named entity 'COVID-19' named entity 'healthcare providers' named entity 'precarity' named entity 'resource allocation' named entity 'off-label' named entity 'research funding' named entity 'clinical trials' named entity 'clinical study' named entity 'COVID' named entity 'US Food and Drug Administration' named entity 'vaccination' named entity 'HCQ' named entity 'clinical practice' named entity 'COVID-19' named entity 'off-label' named entity 'COVID' named entity 'Arizona' named entity 'randomised controlled clinical trials' named entity 'France' named entity 'COVID-19' named entity 'HCQ'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software